Akoya Biosciences, Inc. (AKYA)

$12.68

+0.01 (+0.08%)
Rating:
Recommendation:
-
Symbol AKYA
Price $12.68
Beta 0.000
Volume Avg. 0.17M
Market Cap 480.474M
Shares () -
52 Week Range 8.02-16.57
1y Target Est -
DCF Unlevered AKYA DCF ->
DCF Levered AKYA LDCF ->
ROE -55.41% Strong Sell
ROA -34.29% Strong Sell
Operating Margin -
Debt / Equity 102.82% Buy
P/E -
P/B 5.25 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest AKYA news


Mr. Brian McKelligon
Healthcare
Medical Instruments & Supplies
NASDAQ Global Select

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.